Principal Financial Group
LPCN icon

Principal Financial Group’s Lipocine LPCN Stock Holding History

Principal Financial Group’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,032
Closed -$19K – 2590
2021
Q3 		$19K Sell
1,032
-167
-14% -$3.69K ﹤0.01% 2570
2021
Q2 		$29K Buy
+1,199
New +$28.2K ﹤0.01% 2593

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group's LPCN Position: Q4 2021 in Review

Principal Financial Group sold out of Lipocine (LPCN) in Q4 2021, closing a stake of 1,032 shares — an estimated $19K sold.

Principal Financial Group first reported a position in LPCN in Q2 2021 and held it in 2 quarters. The position peaked at $29K in Q2 2021. 39 funds tracked by Wall St. Rank hold LPCN as of Q4 2021.

  • Principal Financial Group reported no remaining Lipocine position as of Q4 2021 after selling out during the quarter.
  • Principal Financial Group sold 1,032 Lipocine shares in Q4 2021, an estimated $19K.
  • Principal Financial Group first reported a position in Lipocine in Q2 2021 and held it in 2 quarters.
  • Principal Financial Group's Lipocine position peaked at $29K in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Lipocine as of Q4 2021.

Based on Principal Financial Group's 13F filing for Q4 2021, filed 9 Feb 2022.